Cardiovascular Collapse with Intravenous Amiodarone in Children: A Multi-Center Retrospective Cohort Study
- 137 Downloads
To determine the incidence of cardiovascular collapse in children receiving intravenous (IV) amiodarone and to identify the population at risk.
A multicenter study of patients ≤ 18 years of age who received intravenous amiodarone between January 2005 and December 2015. A retrospective analysis was performed to identify patients who developed cardiovascular collapse (bradycardia and/or hypotension).
Of 456 patients who received amiodarone, cardiovascular collapse occurred in 47 patients (10%). Patient risk factors for collapse in a univariate analysis were as follows: age < 3 months (p = 0.04), depressed cardiac function (p < 0.001), blood pressure below 3rd percentile (p < 0.001), high lactate at baseline (p < 0.001). Administration risk factors included bolus administration (p = 0.04), and bolus administration over ≤ 20 min (p = 0.04). In multivariate analysis, age, baseline blood pressure less than 3rd percentile, and rapid bolus delivery were independent risk factors for cardiovascular collapse in the study group. The mortality rate was significantly higher in the collapse group (28% versus 8%).
We found an association between IV amiodarone administration and the risk of developing cardiovascular collapse in a significant subset of children. Extreme caution and careful hemodynamic monitoring is recommended when using IV amiodarone in this population, especially in young infants, hemodynamically compromised patients, and in patients receiving rapid amiodarone bolus administration.
KeywordsArrhythmia Amiodarone Collapse Atrioventricular node Tachycardia Congenital heart defects Pediatrics
None. There are no relationships with industry.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
This study was approved by the review board at each participating center.
For this type of study formal consent is not required.
- 12.Singh BN, Williams EMV. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 39:657–667Google Scholar
- 23.ECC Committee, Subcommittees, Task Forces of the American Heart Association (2005) 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 112:IV1YIV203Google Scholar
- 32.Epstein ML, Kiel EA, Victorica BE (1985) Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia. Pediatrics 75(4):737–740Google Scholar